Investegate |Active Biotech Announcements | Active Biotech: Active Biotech's nomination committee appointed
Investegate announcements from Active Biotech, Active Biotechs nomination committee appointed
Source: investegate.co.uk
📰 Active Biotech News
Page 4 - Active Biotech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Active Biotech. Real-time updates on events, politics, business and more.
Active Biotech's nomination committee appointed
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end
Source: finanznachrichten.de
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech's partner NeoTX at SITC 2021
Lund, Sweden - November 30, 2021 - Active Biotech and its partner NeoTX announced that the preclinical data on naptumomab enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for
United States Hans Kolam Society For Immunotherapy Of Cancer Waltere Washington Convention Center Biotech To Neotx Therapeutics Ltd Annual Meeting
Source: finanznachrichten.de
Active Biotech Interim report January - September 2021
"We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer" THIRD QUARTER
Source: finanznachrichten.de
Active Biotech: New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for presentation
United States University Hospital Bruxelles Capitale Hans Kolam Vrije University University Hospital Dresden
Source: finanznachrichten.de
Investegate |Active Biotech Announcements | Active Biotech: Active Biotech Interim report January
Investegate announcements from Active Biotech, Active Biotech Interim report January - September 2021 
Rate Fix Investegate Announcements Investegate Company Announcements Active Biotech Lobenewswire And Globenewswire
Source: investegate.co.uk
Investegate |Active Biotech Announcements | Active Biotech: New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
Investegate announcements from Active Biotech, New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
United States University Hospital Bruxelles Capitale Hans Kolam American Society Of Hematology Vrije University
Source: investegate.co.uk
Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)
Lund, October 20, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox
Source: finanznachrichten.de
Investegate |Active Biotech Announcements | Active Biotech: Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Investegate announcements from Active Biotech, Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Hans Kolam Dan Vogl International Myeloma Working Group University Of Pennsylvania Abramson Cancer Center Active Biotech
Source: investegate.co.uk
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US
Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been
Hans Kolam Dan Vogl International Myeloma Working Group University Of Pennsylvania Abramson Cancer Center Lund Sweden
Source: finanznachrichten.de